Welcome to Erlend B. Smeland's group:
Lymphomas & Lymphocyte biology

The main focus of our research is the molecular characterization of B cell lymphomas. Lymphomas are cancers derived from the cells of the immune system, and most often they arise from B- or T-cells in the lymph nodes. By the means of high throughput analysis of gene expression, genomic and epigenetic alterations in lymphoma samples we aim to elucidate oncogenetic mechanisms in lymphoma development. We also aim to identify prognostic markers and characterize biologically different subgroups of lymphoma. In functional studies on lymphoma cell lines and normal B-cells we focus on the effects of BMP- and TGF-beta signaling in lymphomas.
An overview of our key achievements can be found here.
The group is a member of Center for Cancer Biomedicine.
Studies of gene expression, genomic and epigenetic alterations in B-cell lymphoma
Epigenetic mechanisms in the development of malignant lymphoma
Intracellular signaling and functional studies in normal and neoplastic B-cells
Lymphoma/Leukemia Molecular Profiling Project (LLMPP)
Contact information:
Department of Immunology, Institute for Cancer Research
The Norwegian Radium Hospital
Montebello
0310 Oslo, Norway
| Phone: | +47 22 78 14 17 (Smeland) |
| +47 22 78 12 66 (Secretary) | |
| +47 22 93 40 00 (switchboard) | |
| Fax: | +47 22 93 55 8 |
Email to E. Smeland: ebs@rr-research.no
Jun 30, 2010
Latest publications
Erlend B. Smeland's group
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression
Proc Natl Acad Sci U S A, 107 (29), 12747-54
PubMed 20543139
Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
Blood (in press)
PubMed 20505157
[Leadership and academic competence]
Tidsskr Nor Laegeforen, 130 (6), 591
PubMed 20348994




Print this page
